196 related articles for article (PubMed ID: 10369073)
41. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
Segev Y; Iqbal J; Lubinski J; Gronwald J; Lynch HT; Moller P; Ghadirian P; Rosen B; Tung N; Kim-Sing C; Foulkes WD; Neuhausen SL; Senter L; Singer CF; Karlan B; Ping S; Narod SA;
Gynecol Oncol; 2013 Jul; 130(1):127-31. PubMed ID: 23562522
[TBL] [Abstract][Full Text] [Related]
42. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer.
Li CI; Malone KE; Weiss NS; Daling JR
J Natl Cancer Inst; 2001 Jul; 93(13):1008-13. PubMed ID: 11438566
[TBL] [Abstract][Full Text] [Related]
43. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
Bertelsen L; Bernstein L; Olsen JH; Mellemkjaer L; Haile RW; Lynch CF; Malone KE; Anton-Culver H; Christensen J; Langholz B; Thomas DC; Begg CB; Capanu M; Ejlertsen B; Stovall M; Boice JD; Shore RE; ; Bernstein JL
J Natl Cancer Inst; 2008 Jan; 100(1):32-40. PubMed ID: 18159070
[TBL] [Abstract][Full Text] [Related]
44. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer.
Bernstein JL; Thompson WD; Risch N; Holford TR
Am J Epidemiol; 1992 Oct; 136(8):925-36. PubMed ID: 1456269
[TBL] [Abstract][Full Text] [Related]
45. Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women.
Santorelli ML; Hirshfield KM; Steinberg MB; Rhoads GG; Lin Y; Demissie K
Ann Epidemiol; 2016 Jun; 26(6):436-40. PubMed ID: 27157863
[TBL] [Abstract][Full Text] [Related]
46. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
47. Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study.
Cortesi L; De Matteis E; Rashid I; Cirilli C; Proietto M; Rivasi F; Federico M
Int J Gynecol Cancer; 2009 Nov; 19(8):1358-63. PubMed ID: 20009890
[TBL] [Abstract][Full Text] [Related]
48. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
[TBL] [Abstract][Full Text] [Related]
49. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
50. Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.
Langballe R; Mellemkjær L; Malone KE; Lynch CF; John EM; Knight JA; Bernstein L; Brooks J; Andersson M; Reiner AS; Liang X; Woods M; Concannon PJ; ; Bernstein JL
Breast Cancer Res; 2016 Jul; 18(1):65. PubMed ID: 27400983
[TBL] [Abstract][Full Text] [Related]
51. Second cancers after adjuvant tamoxifen therapy for breast cancer.
Curtis RE; Boice JD; Shriner DA; Hankey BF; Fraumeni JF
J Natl Cancer Inst; 1996 Jun; 88(12):832-4. PubMed ID: 8637050
[No Abstract] [Full Text] [Related]
52. Risk factors for contralateral breast cancer in Chennai (Madras), India.
Gajalakshmi CK; Shanta V; Hakama M
Int J Epidemiol; 1998 Oct; 27(5):743-50. PubMed ID: 9839728
[TBL] [Abstract][Full Text] [Related]
53. Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review.
Behtash N; Hashemi R; Karimi Zarchi M
Asian Pac J Cancer Prev; 2009; 10(1):163-6. PubMed ID: 19469647
[TBL] [Abstract][Full Text] [Related]
54. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy.
Barakat RR; Gilewski TA; Almadrones L; Saigo PE; Venkatraman E; Hudis C; Hoskins WJ
J Clin Oncol; 2000 Oct; 18(20):3459-63. PubMed ID: 11032585
[TBL] [Abstract][Full Text] [Related]
55. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
56. Endometrial adenosarcoma with adjuvant tamoxifen therapy for primary breast carcinoma.
Jagavkar RS; Shakespeare TP; Stevens MJ
Australas Radiol; 1998 May; 42(2):157-8. PubMed ID: 9599835
[No Abstract] [Full Text] [Related]
57. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden.
Chandanos E; Lindblad M; Jia C; Rubio CA; Ye W; Lagergren J
Br J Cancer; 2006 Jul; 95(1):118-22. PubMed ID: 16755290
[TBL] [Abstract][Full Text] [Related]
58. Eye problems in breast cancer patients treated with tamoxifen.
Paganini-Hill A; Clark LJ
Breast Cancer Res Treat; 2000 Mar; 60(2):167-72. PubMed ID: 10845279
[TBL] [Abstract][Full Text] [Related]
59. The use of Chinese herbal products and its influence on tamoxifen induced endometrial cancer risk among female breast cancer patients: a population-based study.
Tsai YT; Lai JN; Wu CT
J Ethnopharmacol; 2014 Sep; 155(2):1256-62. PubMed ID: 25048609
[TBL] [Abstract][Full Text] [Related]
60. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
